Jun 18, 2026Effective9999999995-26-002072
All companies
Trade Lantern Pharma Inc424B4Jan 15, 2021
Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering
Lantern Pharma Inc
LTRNPublicArchived
Public / ArchivedUnited States(Nasdaq)Best valuation $49.5M1 market
Public listing
Listed· Nasdaq· Listing market: United StatesListing date
Not available
Offer price
Not available
Shares offered
Not available
Offering proceeds
Not available
Sources: sec-edgar, sec-harvest, nasdaq
IPO Calendar · NasdaqIPO
LTRNPrice
$3.88
24h
+2.37%
Valuation
$49.5M
24h volume
$405.21K
Type
IPO
Trade Lantern Pharma IncNow trading publicly. Buy via a broker — opens in a new tab.
IPO Calendar · updated 1h ago
Lantern Pharma Inc IPO public float & lock-up
Public float and locked shares extracted from Lantern Pharma Inc's SEC prospectus. Shares shown are eligible to trade — lock-up expiry does not mean holders have sold or will sell.
Total shares (FD)
10.5M
Public float
4.29M
Locked
6.22M
IPO raise
—
Next unlock
—
Needs review: Could not extract a detailed lock-up release schedule.
Financials
UnprofitableFrom SEC filings, latest FY ending Dec 31, 2025 · CIK 0001763950.
Revenue
—
Net income
-$17.12M
Gross margin
—
Cash
$4.42M
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$17.98M | -$22.22M | -$17.88M | -$14.43M | -$12.59M |
| Net income | -$17.12M | -$20.78M | -$15.96M | -$14.26M | -$12.36M |
| R&D expense | $11.51M | $16.13M | $11.89M | $8.6M | $7.57M |
| Cash & equivalents | $4.42M | $7.51M | $21.94M | $37.2M | $51.52M |
| Total assets | $11.04M | $25.57M | $43.65M | $58.84M | $73.95M |
| Total liabilities | $4.5M | $4.38M | $2.74M | $2.8M | $2.38M |
| Shareholders' equity | $6.53M | $21.19M | $40.91M | $56.04M | $71.57M |
About Lantern Pharma Inc
Lantern Pharma Inc is a healthcare and life-sciences company with a business profile centered on medical products, therapies, diagnostics, or health-related services.
What the company does
- Develops healthcare products, therapies, devices, or services where clinical evidence and regulatory execution are central to the business.
- Operates in a market shaped by product differentiation, development timelines, reimbursement or customer adoption, and disciplined capital allocation.
- Relies on technical, clinical, commercial, and operational teams to move products from development toward broader use.
Business profile
Lantern Pharma Inc belongs to the healthcare and life-sciences market, where product evidence, regulatory pathways, customer adoption, and funding discipline shape long-term outcomes.
SEC IPO filings
EffectiveEDGAR filings resolved from LTRN / CIK 0001763950.
S-1S-1
Jun 12, 2026Filed0001493152-26-028460
Jun 10, 2024Effective9999999995-24-001803
CORRESPfilename1.htm
Jun 6, 2024SEC correspondence0001493152-24-022884
UPLOADfilename1.pdf
Jun 3, 2024SEC correspondence0000000000-24-006316
Jul 12, 2021Effective9999999995-21-002727
CORRESPfilename1.htm
Jul 8, 2021SEC correspondence0001213900-21-036182
UPLOADfilename1.pdf
Jul 7, 2021SEC correspondence0000000000-21-008376
Jan 15, 2021Final prospectus0001213900-21-002604
Jan 14, 2021Effective9999999995-21-000165
CORRESPfilename1.htm
Jan 11, 2021SEC correspondence0001213900-21-001391
Jan 11, 2021Free writing prospectus0001213900-21-001294
Latest Lantern Pharma Inc IPO news
Recent sourced articles classified for IPO relevance, with platform-access noise filtered out where possible.
U.S. Securities and Exchange Commission (SEC)May 14, 2026Market news
Lantern Pharma (NASDAQ: LTRN) announced the closing of its registered direct offering of 2,135,923 shares (or pre-funded warrants in lieu) at $2.06 per share, raising about $4.4 million in gross proceeds, with unregistered warrants potentially adding about $4.85 million upon full exercise. The company stated Rodman & Renshaw acted as the exclusive placement agent and said proceeds are intended for working capital and general corporate purposes.
Lantern Pharma Inc IPO — frequently asked questions
- When did Lantern Pharma Inc go public?
- Lantern Pharma Inc has already gone public and now trades publicly on Nasdaq under the ticker LTRN.
- Can I buy Lantern Pharma Inc stock?
- Yes — Lantern Pharma Inc is publicly traded on Nasdaq as LTRN. You can follow its live price, valuation and post-IPO performance above.
- What is Lantern Pharma Inc's valuation?
- Lantern Pharma Inc's most recent valuation tracked here is $49.5M, derived from live market prices.